This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ERBA Diagnostics, Inc. Reports Third Quarter 2012 Financial Results

Financial Highlights for the Quarter and Nine Months Ended September 30, 2012

Net revenues for the third quarter of 2012 were $3,789,000 compared with $4,060,000 in the third quarter of 2011, a decrease of $271,000 or 6.7%. The decrease in revenue was primarily the result of reduced sales in international markets from our European operations. Net revenue in the nine months ended September 30, 2012 decreased by $196,000, or 1.6%, from the same period last year, with net revenues from domestic operations decreasing by $121,000 or 1.4% and net revenues from European operations decreasing by $75,000 or 1.9%.

Gross profit for the third quarter of 2012 was $2,062,000 or 54.4% of net revenue, compared with $2,086,000 or 51.4% of net revenue for the third quarter of 2011. The decrease in gross profit resulted from lower sales and the increase in gross profit margin percentage was principally as a result of an increase in sales of our proprietary instruments in the US, which have a higher average margin. Gross profit for the nine months ended September 30, 2012 decreased by $172,000, or 2.9%, from the same period last year. The decrease in gross profit was primarily attributable to a decrease in sales.

Operating expenses for the third quarter of 2012 decreased to $2,104,000 from $3,083,000 for the third quarter of 2011. Operating expense for the nine months ended September 30, 2012 decreased to $6,686,000 from $9,726,000 in the nine months ended September 30, 2011 as a result of decreases in all three categories of operating expenses. Selling expenses decreased mainly due to open sales positions in the United States and, in Italy, reduction in workforce and lower commissions. General and administrative expenses decreased as a result of reduction in workforce, reduction in leased office space and reduction in provision for doubtful accounts. Research and development expenses decreased principally due to reduction of research and development activities in the United States and funding of research and development in Italy.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs